Determination of minimum inhibitory concentration of third generation cephalosporins and fluoroquinolones on clinical isolates of Pseudomonas aeruginosa

Authors

  • Bapurao Motiram Bite Department of Pharmacology, Dr. Ulhas Patil Medical College & Hospital, Jalgaon, Maharashtra, India
  • Devendra R. Chaudhari Department of Pharmacology, Dr. Ulhas Patil Medical College & Hospital, Jalgaon, Maharashtra, India
  • Kailash B. Wagh Department of Microbiology, Dr. Ulhas Patil Medical College & Hospital, Jalgaon, Maharashtra, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20151348

Keywords:

Pseudomonas aeruginosa, Minimum inhibitory concentration, Ciprofloxacin, Ofloxacin, Ceftazidime and cefoperazone

Abstract

Background: Pseudomonas aeruginosa has attracted much attention because of its high incidence of nosocomial infections in recent years. The multidrug resistance of these P. aeruginosa isolates plays an important role in the colonization or infection of chronically hospitalized patients. There is continued search for alternative drugs, such fluoroquinolones, and the third generation cephalosporins. The objective of present study was to test the susceptibility of the clinical isolates of P. aeruginosa to antimicrobials like ciprofloxacin, ofloxacin, ceftazidime, and cefoperazone. To determine their minimum inhibitory concentration (MIC) is in resistant isolates.

Methods: The study was conducted in Bacteriology Laboratory, Department of Microbiology, Government Medical College, Miraj. The design of study: in vitro study on 50 clinical isolates of P. aeruginosa.

Results: Among the third generation cephalosporins, ceftazidime (64%) exhibited maximum in vitro activity and among the fluoroquinolones ciprofloxacin (54%) exhibited maximum activity. Out of 50 clinical isolates of P. aeruginosa,17 were resistant to all four antimicrobials,22 were susceptible to all four antimicrobials, and 11 clinical isolates of P. aeruginosa showed mixed susceptibility-resistant pattern.

Conclusion: MIC values for resistant strains of P. aeruginosa ranged from 0.03 to 32 µg/ml for fluoroquinolones and 0.5-512 µg/ml for third generation cephalosporins.

References

Yadav V, Harjai K, Joshi K, Sharma S. Pyelonephritic potential of Pseudomonas aeruginosa in ascending mouse model. Indian J Med Res. 2000;112:93-9.

Mayer I, Nagy E. Investigation of the synergic effects of aminoglycosides. Fluoroquinolones and third generation cephalosporin combination against clinical isolates of Pseudomonas species. J Antimicrob Chemother. 1999;43(5):651-7.

Solomkin JS, Miyagawa CI. Principles of antibiotic therapy. Surg Clin North Am. 1994;74(3):497-517.

Daniel J, Thomas M, Shanmugam J. In vitro susceptibility of Gram-negative bacteria to amikacin and its comparison with three other aminoglycoside antibiotics. Indian J Pathol Microbiol. 1985;28:115-9.

Fish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother. 2002;50(6):1045-9.

Gould IM, Milne K. In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin. J Antimicrob Chemother. 1997;39(1):53-61.

Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45(4):493-6.

Anderson TG. Testing of susceptibility to antimicrobial agents and assay of antimicrobial agents in body fluids. In: Blair JF, Lennette EH, Jruant JP, editors. Manual of Clinical Microbiology. Washington, DC: Am Society Microbiology; 1970: 303-5.

Eliopouos GM. In: Lorian V, editor. Antibiotic in Laboratory Medicine. 4th Edition. London: Williams and Wilkins; 2012.

Wilson WS, C’hau PY, Leung YK, Livemiore DM. In vitro activities of Ro 17/23- 2301 and aztreonam compared with those of other new beta lactam antibiotics against clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1985;27(5):872-3.

Giamarellous H, Petrikkos G. Ciprofloxacin interactions with imipenam and amikacin against multi resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1987;31(6):959-61.

Chaware SM, Vijay K, Singh AK, Bhatnagar SK, Shankhdhar VK. Infection in burn wounds recent trends in microbial flora and antibiotic sensitivity and resistance. Indian J Burns. 2004;12(1):51-2.

Mehta M, Dutta P, Gupta V. Bacterial isolates from burn wound infections and their antibiograms: a eight year study. Indian J Plastic Surg. 2007;40:25-8.

Rastegar Lari AR, Alaghehbandan R, Akhlaghi L. Burn wound infections and antimicrobial resistance in Tehran, Iran: an increasing problem. Ann Burns Fire Disasters. 2005;18(2):68-73.

Sarkar B, Biswas D, Prasad R, Sharma JP. A clinicomicrobiological study on the importance of pseudomonas in nosocomially infected ICU patients, with special reference to metallo beta1-lactamase production. Indian J Pathol Microbiol. 2006;49(1):44-8.

Wu YL, Scott EM, Po AL, Tariq VN. Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations. APMIS. 1999;107(6):585-92.

Downloads

Published

2017-01-16

How to Cite

Bite, B. M., Chaudhari, D. R., & Wagh, K. B. (2017). Determination of minimum inhibitory concentration of third generation cephalosporins and fluoroquinolones on clinical isolates of Pseudomonas aeruginosa. International Journal of Basic & Clinical Pharmacology, 4(6), 1142–1146. https://doi.org/10.18203/2319-2003.ijbcp20151348

Issue

Section

Original Research Articles